Characterization of lactotransferrin receptor in epithelial cell lines from non-malignant human breast, benign mastopathies and breast carcinomas.

The aim of this study was to investigate the presence of lactotransferrin receptor on breast non-malignant SV-40 immortalized cells (HBL100 and NB54T), benign mastopathy immortalized cells (NPM14T and NPM21T1), hst oncogene transformed HBL100 cell line (tumorigenic HH9 cells) and breast carcinoma cells (T47D, MCF7, VHB1, BT20 and MDA-MB 231). Flow cytometry analyses of the reversible binding of lactotransferrin labeled on its glycan moiety with fluorescein indicate, for the first time, that all these epithelial breast cell lines, express a specific lactotransferrin receptor. The binding parameters of [125I]-lactotransferrin to non-malignant cells, hst oncogene transformed cells and benign mastopathy cells are of the same order of magnitude as those determined for activated lymphocytes and for cancerous breast cell lines, except for MDA-MB 231 cells. MDA-MB 231 cells bind lactotransferrin with the lowest affinity and, in contrast to other analyzed breast cells, are not recognized by antibodies directed against lymphocyte lactotransferrin receptor. These results suggest that MDA-MB 231 lactotransferrin receptor is different from that characterized at the cell surface of other breast cells. In conclusion, since the lactotransferrin receptor expression was not enhanced at the surface of cancerous cell lines and was not altered by the oncogene transformation of a normal cell (HBL100) to a tumorigenic cell (HH9), the lactotransferrin receptor cannot be considered as a marker of tumor progression.